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INTRODUCTION
Multi-component macromolecular complexes that execute
the fundamental nuclear processes of DNA replication,
transcription and splicing are organized in discrete subnuclear
foci (Lawrence et al., 1989; Nickerson et al., 1995; Stein et al.,
2000; Wei et al., 1998; Wei et al., 1999). Specificity of gene
expression is conferred by transcription factors that respond to
physiological cues and intracellular signals. Many cell-type-
restricted transcription factors are targeted to multi-subunit
complexes that reside in distinct subnuclear domains (Bidwell
et al., 1998; DeFranco and Guerrero, 2000; Stein et al., 2000),
and support activation or repression of tissue-specific genes.
These macromolecular complexes involved in transcription are
dynamic, yet remain stably associated with the nucleus
following removal of soluble proteins and chromatin.
Examples of regulatory proteins that are targeted to
intranuclear foci are Runx/Cbfa/AML factors (Merriman et al.,
1995; Stein et al., 2000; Zeng et al., 1997; Zeng et al., 1998),
the multi-functional YY1 protein (Guo et al., 1995; McNeil et
al., 1998), steroid hormone receptors (glucocorticoid receptor,
estrogen receptor, vitamin D receptor, androgen receptor)
(DeFranco and Guerrero, 2000; Getzenberg et al., 1991;
Getzenberg and Coffey, 1990; Stenoien et al., 2001; van
Steensel et al., 1995a; van Steensel et al., 1995b), Pit1
transcription factor (Mancini et al., 1999), the corepressor
transducin-like enhancer (TLE; Javed et al., 2000), histone
deacetylases and acetyl transferases (reviewed in Davie, 1997;
Davie, 1998; Davie and Chadee, 1998), and SWI/SNF
chromatin-modifying complexes (Reyes et al., 1997). The
mechanisms that govern the assembly of these compositely
organized, multi-functional complexes at the subnuclear level
may be essential for the regulation of gene expression.
Localizing regulatory proteins to specialized sites within the
nucleus involves nuclear import, in situ interactions with
chromatin and transcriptional co-regulators, and subnuclear
targeting. Mechanisms controlling nuclear import and
interactions of transcription factors with DNA and co-
regulators are well defined (Gorlich and Kutay, 1999; Gorlich
and Mattaj, 1996; Lemon and Tjian, 2000). However,
molecular determinants that target regulatory factors to specific
subnuclear domains involved in transcription remain to be
identified.
Modifications in multiple parameters of nuclear architecture
occur during progression of osteoblast differentiation, as
reflected by subnuclear compartmentalization of gene
regulatory proteins (Bidwell et al., 1993; Dworetzky et al.,
1990) and alterations in chromatin structure of the bone-
specific osteocalcin gene (Montecino et al., 1994; Montecino
et al., 1996b; Montecino et al., 1996a; Montecino et al., 1999b;
Montecino et al., 1999a). Bone-restricted expression of the
osteocalcin gene provides a paradigm for defining the
mechanisms underlying tissue-specific transcription in the
context of nuclear and chromatin architecture. Two osteocalcin
gene regulatory factors, nuclear matrix protein 1 (NMP1)
and NMP2, have been identified as YY1 and Runx2/Cbfa1,
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Key components of DNA replication and the basal
transcriptional machinery as well as several tissue-specific
transcription factors are compartmentalized in specialized
nuclear domains. In the present study, we show that
determinants of subnuclear targeting of the bone-related
Runx2/Cbfa1 protein reside in the C-terminus. With a
panel of C-terminal mutations, we further demonstrate
that targeting of Runx2 to discrete subnuclear foci is
mediated by a 38 amino acid sequence (aa 397-434). This
nuclear matrix-targeting signal (NMTS) directs the
heterologous Gal4 protein to nuclear-matrix-associated
Runx2 foci and enhances transactivation of a luciferase
gene controlled by Gal4 binding sites. Importantly, we
show that targeting of Runx2 to the NM-associated foci
contributes to transactivation of the osteoblast-specific
osteocalcin gene in osseous cells. Taken together, these
findings identify a critical component of the mechanisms
mediating Runx2 targeting to subnuclear foci and provide
functional linkage between subnuclear organization of
Runx2 and bone-specific transcriptional control.
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respectively (Guo et al., 1995; Merriman et al., 1995). Both
factors are intimately associated with control of steroid-
hormone-responsive and tissue-specific transcription (Guo et
al., 1997; Javed et al., 1999), suggesting functional coupling
between cell signaling and nuclear architecture. 
The Runx/Cbfa proteins (e.g. Runx1/AML-1, Runx2/Cbfa1)
play vital roles in cellular differentiation and development.
Gene ablation studies have revealed that Runx1 is required for
definitive hematopoiesis whereas Runx2 is essential for bone
formation (Komori et al., 1997; Otto et al., 1997; Wang et al.,
1996). Runx proteins interact with the core DNA sequence
(RACCRCW) through the highly conserved runt homology
domain (Meyers et al., 1993; Ogawa et al., 1993). These
proteins exert their effects in part by modifying chromatin
organization of tissue-specific gene promoters (Gutierrez et al.,
2000; Javed et al., 1999; Montecino et al., 1996b). In addition,
the activities of Runx factors are modulated by interactions
with coregulatory proteins (e.g. Groucho/TLE, Yes-associated
protein (YAP), Smad) that contribute to the integration of cell-
signaling pathways in response to physiological cues (Aronson
et al., 1997; Hanai et al., 1999; Javed et al., 2000; Levanon et
al., 1998; McLarren et al., 2000; Yagi et al., 1999; Zhang et
al., 2000a). Runx proteins reside in discrete subnuclear foci
and colocalize with transcriptional regulators which activate or
repress Runx-dependent genes (Javed et al., 2000; Prince et al.,
2001; Zeng et al., 1997; Zeng et al., 1998). 
The identification of Runx2/Cbfa1 as a nuclear-matrix-
associated tissue-specific transcription factor (Banerjee et al.,
1997; Bidwell et al., 1993; Ducy et al., 1997; Merriman
et al., 1995) provided the initial insight into the linkage
between subnuclear compartmentalization and osteoblast
differentiation. Therefore, one important question is how
Runx2 is directed to specific subnuclear domains and whether
intranuclear localization contributes to regulation of bone-
specific genes. In the present study, we have defined a 38 amino
acid segment in the C-terminus of Runx2 that is responsible
for subnuclear targeting of the transcription factor. Moreover,
this nuclear-matrix-targeting signal (NMTS) is sufficient to
direct a heterologous protein to the nuclear-matrix-associated
foci containing Runx2. Furthermore, subnuclear targeting of
Runx2 contributes to transcriptional regulation of the bone-
specific osteocalcin gene.
MATERIALS AND METHODS
Cell cultures and transient transfections
Rat osteosarcoma ROS 17/2.8 and human cervical carcinoma HeLa
cells were maintained and transfected essentially as reported
previously (Javed et al., 2000).
Plasmid constructs
An epitope tag version of pcDNA 3.1 (pHA) was generated by
inserting the HA-tag in the HindIII-KpnI sites to replace the His-
Xpress tag of pcDNA 3.1 (Invitrogen, Carlsbad, CA). HA-tag Runx2
was constructed by cloning a cDNA encoding Runx2 in the BamHI-
XbaI sites of pHA to generate pHA-Runx2 (1-528). pHA-Runx2 (1-
516) was generated by digesting pHA-Runx2 (1-528) with EcoRI and
XbaI followed by fill-in reaction with DNA polymerase I Klenow
fragment and blunt end ligation. pHA-Runx2 (1-376) was generated
by the addition of a stop codon by PCR-based site-directed
mutagenesis. The Runx2 mutant D 397-434 was constructed by PCR-
based nest-deletion mutagenesis. Internal deletions of Runx2, that is,
D 400-467 and D 433-467, were generated by digesting pHA-Runx2
with SmaI and BspmI-SmaI, respectively. To generate Gal4 DNA-
binding domain (DBD) (1-147) fused with Runx2 (397-434), the
aforementioned fragments of Runx2 were amplified with EcoRV-PstI
sites incorporated into the primers and the digested PCR products
were inserted in frame downstream of the Gal4 DBD. The reading
frames of deletion mutants were confirmed by sequencing.
Nuclear extracts and electrophoretic mobility shift assay
Preparation of nuclear extracts from cells expressing proteins of
interest and the protocol for electrophoretic mobility shift assays have
been described (Javed et al., 1999). The wild-type Runx consensus 5 ¢
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Fig. 1. Endogenous Runx2 is
associated with the nuclear
matrix in osteoblastic cells.
ROS 17/2.8 cells grown on
gelatin-coated coverslips
were processed for whole cell
(WC) or nuclear matrix-
intermediate filament (NM-
IF) preparations and in situ
immunofluorescence as
described in Materials and
Methods. Rabbit polyclonal
antibody against Runx2 was
used at a dilution of 1:200
(Javed et al., 2001).
Secondary antibody used was
Alexa 468 (goat against
mouse) at a dilution of 1:800.
The middle panel shows 4¢ ,6-
diamidino-2-phenylindole
(DAPI) staining, which is
absent in NM-IF preparation
as chromatin has been
removed. Right panel shows
phase contrast image of the
same cell. 
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CGAGTATTGTGGTTAATACG 3¢ (Meyers et al., 1993) was
synthesized using a Beckman synthesizer 2000. The Runx binding site
is indicated in bold.
In situ immunofluorescence microscopy
ROS 17/2.8 or HeLa cells grown on gelatin-coated coverslips were
transfected with 0.5 m g cytomegalovirus (CMV)-driven wild-type
Runx2, its deletion mutants or with expression constructs for Gal4
DBD fused to the NMTS of Runx2. Cells were extracted for in situ
nuclear matrix preparations and were analyzed by digital microscopy
essentially as described (Javed et al., 2000). HA-tag full-length or
deletion mutants of Runx2 were detected by a mouse monoclonal
antibody against HA-tag at a dilution of 1:3000 (Zeng et al., 1997).
Expression of the Gal4 DBD fusion constructs was detected by a
mouse monoclonal antibody against Gal4 DBD (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) at a dilution of 1:1000. We used
either Alexa 488 anti-rabbit or Alexa 568 anti-mouse secondary
antibodies (Molecular Probes, Eugene, OR). To detect endogenous
Runx2 in ROS 17/2.8 cells, the rabbit polyclonal antibody (Javed et
al., 2001) was used at a dilution of 1:200. Mouse monoclonal
antibodies were used to detect SC35, RNA processing speckles
(1:500) (Spector et al., 1991), promyelocytic leukemia (PML) bodies
(1:1000; Santa Cruz Biotechnology Inc.), coilin (1:100 (Smith et al.,
1995)) and nucleolin (1:300; provided by P.-K. Chan, Baylor College
of Medicine, TX).
Biochemical fractionation and western blotting
Cells were biochemically fractionated using a protocol previously
described (Merriman et al., 1995), with several modifications. HeLa
cells grown on 100 mm plates were transfected with 10 m g of full-length
Fig. 2. Runx2 resides in distinct subnuclear domains. HeLa cells transiently expressing Runx2 were processed for NM-IF preparation and double-
label immunofluorescence to assess to what extent it colocalizes with nucleolin (A), coilin (B), SC35 (C) and PML bodies (D). Arrowheads point
to distinct coilin and Runx2 domains (B) and PML bodies and Runx2 (D). Bars (2 m m) represent the relative magnification of the images.
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Runx2 or deletion constructs and subcellular fractions were prepared
24 hours after transfection. For whole-cell lysate, cells were harvested
in 300 m l direct lysis buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM
Tris-HCl (pH 6.8), 0.002% bromophenol blue, 10 mM DTT and 1·
Complete™ protease inhibitors (Roche, Indianapolis, IN)). Samples
were immediately boiled for 5 minutes and stored at - 70°C until used.
For subcellular fractionation, cells were collected in ice-cold 1· PBS
containing 1· CompleteÔ protease inhibitors. Cell pellets were
resuspended in 300 m l CSK buffer (100 mM NaCl, 0.3 M sucrose, 10
mM Pipes, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, pH 6.8)
for 10 minutes on ice. Extracted cells were then subjected to
centrifugation to collect nuclei. The supernatant containing cytosolic
proteins was frozen in liquid nitrogen and stored in aliquots at - 70°C.
Nuclei were extracted with 300 m l digestion buffer (50 mM NaCl, 0.3
M sucrose, 10 mM Pipes, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-
100, pH 6.8) containing 400 U DNaseI (Roche) for 30 minutes at room
temperature. DNaseI activity was stopped by adding 2 M ammonium
sulfate to a final concentration of 250 mM for 5 minutes at room
temperature. Extracted nuclei were centrifuged to separate soluble
nuclear proteins (chromatin fraction) and insoluble nuclear-matrix-
intermediate filament fraction (NM-IF). The NM-IF fraction was then
boiled in 300 m l of direct lysis buffer for 5 minutes. The same volume
percentage of each fraction was analyzed by 10% SDS-PAGE.
Separated proteins were transferred to a PVDF membrane (Millipore)
and processed for western blotting as described elsewhere (Ausubel et
al., 1997). Antibodies were purchased from Santa Cruz and used in the
following dilutions: monoclonal antibody against HA tag (SC-7392;
1:3000), goat polyclonal antibody against lamin B (SC-6217; 1:1000),
and the corresponding horse-radish peroxidase (HRP)-conjugated
secondary antibodies (SC-2042; 1:2000). Immunoreactivity was
assessed using an ECL chemiluminescence kit (Amersham-Pharmacia,
Piscataway, NJ).
Reporter gene activity assays
Rat osteosarcoma (ROS 17/2.8) or HeLa cells grown on six-well
plates were transfected with 0.1 m g of expression vector for Runx2 or
its deletion mutants along with 1 m g of - 208 osteocalcin-CAT (OC-
CAT), spanning one Runx-binding site (site C) (Banerjee et al., 1996;
Javed et al., 1999) of the rat osteocalcin promoter. Rous sarcoma
virus-luciferase (RSV-Luc) was included as an internal control for
transfection efficiency. Cells were harvested 24 hours after
transfection and were processed for CAT (chloramphenicol acetyl
transferase) assays as described (Javed et al., 1999). All quantitation
was done on the Storm PhosphorImager using ImageQuant software
(ABI/Molecular Dynamics, Sunnyvale, CA). The luciferase activity
was assessed with Luciferase Assay Kit (Promega, Madison, WI)
from the same cell lysate. CAT values were normalized with respect
to the luciferase values. The graphs are representative of three
independent experiments (n=6 in each experiment) with different
DNA preparations.
RESULTS
Runx2 resides in unique subnuclear domains
To address the mechanism that directs bone-tissue-related
Runx2 protein to nuclear-matrix-associated foci, we initially
assessed the subnuclear distribution of endogenous Runx2 in
ROS 17/2.8 cells. As shown in Fig. 1, endogenous Runx2
protein is localized in numerous punctate subnuclear foci and
remain associated with the NM-IF scaffold following detergent
extraction and chromatin removal.
We assessed whether Runx2 colocalizes with previously
established subnuclear domains or whether it is distributed
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Fig. 3. Deletion mutants of
Runx2 express at comparable
levels and exhibit unaltered
DNA binding activity.
(A) Runx2 deletion mutants.
The black box shows highly
conserved runt homology
domain (RHD). The dark gray
box represents the amino acid
sequences in Runx2
homologous to the NMTS of
Runx1 whereas the C-terminal
light gray box represents the
highly conserved VWRPY
domain. (B) HeLa cells grown
in 100 mm plates were
transfected at 50-60%
confluence with 10 m g of the
expression construct for each of
the mentioned deletion mutants.
The cells were harvested 24
hours after transfection in direct
lysis buffer and proteins were
separated by SDS-PAGE. The
western blotting was carried out
as described. The blots were
incubated with monoclonal
antibody against HA tag (Santa
Cruz; dilution 1:3000) followed by incubation with HRP-conjugated secondary antibody raised against mouse (Santa Cruz; dilution 1:2000) to
detect the proteins. Cdk2 antibody (1:5000) was used as an internal control. (C) HeLa cells transiently expressing mentioned deletion mutants
were processed for nuclear extract preparation. Radioactively labeled Runx consensus sequence was used as probe. The mentioned proteins
were used in increasing concentrations, that is, 2, 4 and 8 m g in electrophoretic mobility shift assay; EV (empty vector) indicates that cells were
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in distinct foci. Cells transiently expressing Runx2 were
evaluated for the relative location of Runx2 and endogenous
PML bodies (Chang et al., 1995), SC35 RNA processing
speckles (reviewed by Shopland and Lawrence, 2000),
nucleolar protein nucleolin (Dickinson et al., 1992) or coiled
body protein coilin (Puvion-Dutilleul et al., 1995) by
immunofluorescence microscopy. To facilitate antibody
compatibility, we prepared a construct expressing epitope
Fig. 4. The region
responsible for subnuclear
targeting of Runx2 resides in
the C-terminus. ROS 17/2.8
cells grown on gelatin-coated
coverslips were transfected
with (A) Runx2 (1-528)
(B) Runx2 (1-516) and (C)
Runx2 (1-376). The cells
were then processed for NM-




against HA tag (1:3000)
followed by incubation with
Alexa 568 conjugated
secondary antibody (1:800)
to detect the expressed
proteins. Images were taken
using Zeiss Axioplan digital
microscope and Metamorph
software was used for bio
imaging. Bars (2 m m)
represent the relative
magnification of the images.
Fig. 5. Runx2 has a functional
NMTS. ROS 17/2.8 cells
grown on gelatin-coated
coverslips were transfected
with (A) Runx2 (400-467)
(B) Runx2 (397-434) and (C)
Runx2 (433-467). The cells
were then processed for NM-
IF preparation and in situ
immunofluorescence as for
Fig. 4. Bars (2 m m) represent
the relative magnification of
images.
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tagged Runx2 and transfected into HeLa cells that lack
endogenous Runx2. As shown in Fig. 2, Runx2 does not
colocalize with any of these proteins, indicating that Runx2
resides in unique subnuclear domains.
Delineation of the NMTS of Runx2
To delineate the region of Runx2 responsible for nuclear matrix
targeting, several deletion mutants of Runx2 were generated.
All of the deletion mutants showed comparable levels of
expression and exhibited normal DNA binding activity (Fig. 3).
We analyzed the in situ subnuclear localization of these Runx2
mutants in nuclear matrix preparations of ROS 17/2.8 and HeLa
cells. As shown in Fig. 4A, transiently expressed full-length
Runx2 (1-528) is distributed in discrete subnuclear foci and is
resistant to high salt extraction. Deletion of 12 amino acids (1-
516), which removes the highly conserved VWRPY domain,
has no effect on NM association of the protein (Fig. 4B). The
VWRPY domain is responsible for interaction with the highly
conserved Groucho/TLE class of repressors, which also
associate with the NM (Chen and Courey 2000; Javed et al.,
2000). The presence of Runx2 mutant lacking the VWRPY
domain (1-516) in the NM-IF preparation indicates that
Groucho/TLE proteins are not required for retention of Runx2
in NM-associated foci. Strikingly, removal of amino acids 377
to 528 in the C-terminus in Runx2 mutant (1-376) does not
influence competency for nuclear import, but subnuclear
retention of this Runx2 mutant is abrogated. Taken together,
these results demonstrate that the sequences responsible for
subnuclear distribution of Runx2 are distinct from those for
nuclear import and that the determinants of subnuclear targeting
reside in the C-terminal region of the protein (Fig. 4C).
We applied both in situ immunofluorescence and
biochemical approaches to delineate the specific amino acid
sequences of Runx2 responsible for intranuclear localization
(Fig. 5; Fig. 6). Several internal deletion mutants of Runx2
were examined. The results indicate that deletion of aa 400-
467 abolishes the association of Runx2 ( D 400-467) with
subnuclear foci in the nuclear matrix (Fig. 5A). Deletion of
amino acids 397-434 eliminates NM association of Runx2
(D 397-434) (Fig. 5B), whereas removal of amino acids 433-
467 does not affect association of the protein with the NM-IF
scaffold (Fig. 5C). Thus, our results establish that a 38 amino
acid segment of Runx2 is required for in situ subnuclear
targeting. We also monitored the biochemical partitioning of
Runx2 protein among cytoplasmic, chromatin and nuclear
matrix compartments by western blot analysis of subcellular
fractions from cells transiently expressing Runx2 deletion
mutants (Fig. 6). Mutant proteins containing amino acids 397-
434 are detected in the NM-IF compartment, but mutants
lacking this region [i.e. Runx2 (1-376), Runx2 (D 400-467),
Runx2 (D 397-434)] are observed only in the cytoplasmic
(CSK) and/or chromatin fractions. For comparison, lamin B, a
component of the lamina pore complex, is exclusively detected
in the NM-IF indicating that principal parameters of nuclear
architecture have been preserved (data not shown). We
conclude that deletion of the NMTS dramatically alters the
subnuclear compartmentalization of Runx2 mutant proteins.
The NMTS region is phylogenetically conserved in diverse
vertebrate species (Fig. 7), which is consistent with the
importance of the NMTS in intranuclear targeting.
The NMTS of Runx2 can target a heterologous
protein to Runx foci
We directly addressed the ability of the Runx2 NMTS to target
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Fig. 6. Subcellular fractionation of HeLa cells expressing deletion
mutants of Runx2. HeLa cells expressing mentioned deletion
mutants were subjected to biochemical fractionation as detailed in
Materials and Methods. The fractions were processed for SDS-PAGE
followed by western blotting. Monoclonal antibody against HA tag
was used to detect the expressed proteins.
Fig. 7. Conservation of the nuclear matrix-
targeting signal in vertebrate species.
Amino acid sequence alignments of the
indicated Runx2 (Cbfa1/AML3), Runx1
(Cbfa2/AML1), and Runx 3
(Cbfa3/AML2/PEBP2a A) proteins from
different vertebrate species including two
species of fish (Danio rerio (Danio),
zebrafish; Oryzias latipes (Oryzi), Japanese
killifish or medaka). Alignments were
performed using CLUSTALW and
graphically depicted using the GeneDoc
software developed by K. B. Nicholas and
H. B. Nicholas. Amino acids were colored
on the basis of similarities in physiochemical properties (H,K,R, dark blue; N,Q, light blue; S,T, orange; L,I,V, dark gray, A,G, light gray;
F,Y,W, maroon; M,C, yellow; P, white). None of the amino acid sequences contains negatively charged amino acids (D,E). 
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a heterologous protein to NM-associated Runx2 foci. We
generated a construct encoding a protein in which the NMTS
is fused to the Gal4 DNA binding domain (Gal4-NMTS). Cells
were transfected with constructs expressing the Gal4 DNA
binding domain alone or with the Gal4-NMTS fusion protein.
The subcellular distribution of these proteins was analyzed in
whole-cell and NM-IF preparations by immunofluorescence
microscopy (Fig. 8A). Both proteins are imported into the
nucleus, which is consistent with the presence of a nuclear
import signal. However, only the Gal4 protein that is fused with
the 38 amino acid NMTS is retained in the NM-IF
preparations. Our results establish that the Runx2 NMTS
functions as an autonomous subnuclear targeting signal.
To assess whether the NMTS can specify the subnuclear
location of a heterologous protein, we tested the ability of the
NMTS to target the Gal4 protein to the same subnuclear foci
as those containing the endogenous Runx2 in osseous cells. We
performed double-label immunofluorescence microscopy and
compared the signals of the Gal4-NMTS protein with those for
Runx2 (Fig. 8B). We observed that the NMTS of Runx2 targets
Gal4 to NM-associated foci where the endogenous Runx2
resides as evidenced by a complete overlap of signals in the
merged image. Therefore, our data strongly suggest that the
NMTS not only mediates interactions with components of
nuclear architecture but also specifies the subnuclear location
of the protein.
We assessed whether subnuclear targeting of the Gal4 DBD is
functionally linked to transcriptional control of a Gal4-responsive
Fig. 8. (A) The NMTS of Runx2
is functionally autonomous. HeLa
cells grown on coverslips were
transfected with Gal4 or Gal4-
NMTS Runx2 and the cells were
then processed for NM-IF
preparation and in situ
immunofluorescence as described.
The expression of the proteins
was detected by monoclonal
antibody against Gal4 DBD
(1:1000). (B) The NMTS of
Runx2 can target a heterologous
protein to the NM-associated
Runx2 foci. ROS 17/2.8 cells
grown on gelatin-coated
coverslips were transfected with
Gal4-NMTS Runx2 and were
processed for double immuno
labeling for endogenous Runx2
and over-expressed Gal4 DBD
constructs. (C) The NMTS of
Runx2 exhibits mild
transactivation. The HeLa cells
stably transfected with luciferase
reporter carrying five Gal4
binding sites upstream of transcription initiation site were transiently transfected with Gal4 DBD or Gal4-NMTS. Cells were harvested in




















promoter. We transfected the Gal4 DBD or the Gal4-NMTS into
HeLa cells containing a genomically integrated luciferase gene
driven by Gal4 binding sites. As shown in Fig. 8C, the Gal4-
NMTS protein mediates 2.5-fold activation relative to Gal4
DBD alone. Thus, our data indicate that the NMTS supports
transcriptional activation of a Gal4-responsive promoter.
The NMTS of Runx2 contributes to activation of the
bone-specific osteocalcin gene
We addressed the biological consequences of NMTS-mediated
intranuclear targeting of Runx2 on osteoblast-specific gene
expression. We compared the transcriptional activities of wild-
type Runx2 and mutants lacking the NMTS by monitoring their
ability to enhance promoter activity of the rat osteocalcin gene
(Fig. 9). Wild-type Runx2 (1-528) activates osteocalcin gene
transcription 7-8 fold. This response is reduced to 1.5-2 fold for
the Runx2 (1-376) mutant, which lacks the entire C-terminus
spanning the NMTS. This result demonstrates that the entire C-
terminus of Runx2 is required for optimal physiological activity
of the protein. Runx2 mutants missing only the NMTS (D 397-
434) or 68 amino acids including the NMTS (D 400-467) exhibit
dramatically reduced transactivation potential – similar to the
Runx2 mutant (1-376) – compared to wild-type Runx2 (1-528).
Runx2 mutants in which other segments of the C-terminus were
deleted (i.e. Runx2 (D 433-467) or Runx2 (1-516)) show only
moderately reduced transactivation potential (i.e. from 7-8 fold
to 4-5 fold). Interestingly, all three mutants displaying severely
reduced transcriptional activity are expressed at comparable
levels, are imported into the nucleus (Figs 4, 5) and have normal
DNA binding activity (Fig. 3), yet exhibit compromised
subnuclear targeting (Figs 4-6). These data strongly suggest that
subnuclear targeting of Runx2 is obligatory for optimal
transcriptional activity of the protein.
DISCUSSION
In the present study, we have characterized an important
component of the mechanisms mediating the assembly,
organization and activities of regulatory complexes within the
nucleus. We report the determinants of subnuclear targeting for
the bone-related Runx2 transcription factor. We demonstrate that
the endogenous Runx2 in osteoblastic cells is localized in distinct
NM-associated subnuclear foci that are resistant to biochemical
fractionation and chromatin removal from the nucleus. Using a
panel of deletion mutants, we find that a 38 amino acid sequence
of Runx2 (aa 397-434), designated the NMTS, is necessary and
sufficient for retention of Runx2 in subnuclear foci. The NMTS
of Runx2 functions autonomously and can target a heterologous
protein to subnuclear Runx2 foci. The regulatory consequences
of NMTS-mediated subnuclear targeting are directly indicated by
a significant contribution to transactivation of the bone-specific
osteocalcin gene, which is physiologically expressed in
osteoblasts. The conservation of the NMTS in the Runx1, Runx2
and Runx3 proteins of diverse vertebrate species (Fig. 7) suggests
that intranuclear targeting represents a conserved function in
transcriptional control of tissue-specific gene expression. The
similarity in subnuclear targeting signals of the three Runx
proteins indicates that similar mechanisms may govern
subnuclear distribution of Runx proteins.
Components of nuclear architecture may influence the
spatial organization of nucleic acids and regulatory proteins.
Two types of interactions have been reported: stable
interactions through nuclear-matrix-associated sequences
designated MARs (Bode et al., 2000) and dynamic interactions
involving transcription factors and tissue-specific nuclear
matrix proteins (Bidwell et al., 1993; Dworetzky et al., 1992;
van Wijnen et al., 1993). Distinct transcription factors exhibit
characteristic subnuclear distributions. These regulatory
proteins interact with DNA in a sequence-specific manner and
associate with the components of nuclear architecture at
distinct subnuclear sites. Such specific intranuclear domains
can provide an environment that increases the probability of
achieving a threshold for protein-DNA and protein-protein
interactions to organize the regulatory machinery required for
tissue-specific transcription.
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Fig. 9. Transactivation of bone-tissue-specific
marker, osteocalcin, is dependent on association of
Runx2 with nuclear matrix. HeLa cells grown on
six- well plates were transfected with 0.1 m g of the
mentioned expression constructs along with 1 m g
p208 OC CAT and 0.05 m g RSV-Luc as internal
control for transfection efficiency. Cells were
harvested in 300 m l of 1 · Reporter Lysis Buffer
(Promega) and the lysates were processed for CAT
and luciferase assays as described. The CAT values
were normalized with respective luciferase values
and were plotted as fold activity relative to empty
vector control. The graph is representative of three
independent experiments each with n=6 (±s.e.m.).
An example of a typical CAT assay is shown.
3101Subnuclear targeting of Runx2/Cbfa1
The Runx family of transcription factors provides a paradigm
to understand the link between transcriptional regulation and
nuclear architecture. Gene ablation studies suggest that Runx2
is a principal regulator of bone formation in vivo (Komori et al.,
1997; Otto et al., 1997). Recently, a nonsense mutation has been
reported in exon 7, which results in expression of Runx2 lacking
the NMTS (Zhang et al., 2000b). This natural mutation causes
the autosomal dominant human disease the cleidocranial
dysplasia (CCD), which is characterized by severe craniofacial
abnormalities. The C-terminus of Runx1 containing the NMTS
is a frequent target of chromosomal translocations in leukemia
(Lutterbach et al., 2000; Rowley, 1998), which is consistent with
physiological implications for intranuclear trafficking. Loss of
the NMTS and aberrant subnuclear targeting of Runx1 has been
implicated in the pathology of leukemia. Compromised
subnuclear targeting of Runx2 may also contribute to the
development of the CCD phenotype. Additional characterization
of mechanisms that control localization of Runx proteins at
subnuclear sites should contribute to understanding further the
development of hematopoietic and skeletal disorders.
Our data suggest that optimal transactivation of the bone-
restricted osteocalcin gene by Runx2 is dependent on
subnuclear localization and/or intranuclear targeting of the
protein. Interestingly, the NMTS of Runx2 we have identified
in this study is contained within a larger region that has a
transactivation function (Kanno et al., 1998; Thirunavukkarasu
et al., 1998). Moreover, this region is responsible for the
interaction of Runx2 with several proteins and integrates
regulatory cues related to transforming growth factor b (TGF-
b) /bone morphogenetic protein 2 (BMP2) and Yes/Crk/Src
signaling pathways (Hanai et al., 1999; Yagi et al., 1999; Zhang
et al., 2000a). We propose that extracellular signaling and
protein-protein interactions involving the C-terminus of Runx2
and bone-specific transcriptional control may converge at
subnuclear foci to optimize physiological responses.
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